S4 Table. Pooled incidence rate of serious adverse event at entire of treatment

Treatment regimens	No. of studies	No. of subjects	No. of having events	Rate (%) of events (95% CI)
PR	9	544	42	7.5 (5.2, 9.7)
SMV plus PR	5	1,032	55	5.0 (3.6, 6.3)
DCV plus PR	2	353	28	7.9 (5.1, 10.7)
SOF plus PR	2	144	6	4.10 (0.0, 9.6)
SOF plus LDV	3	903	29	3.0 (1.3, 4.7)
SOF plus DCV	1	100	7	7.0 (2.0, 12.0)
PrOD	1	79	2	2.5 (0.3, 8.8)
SOF plus LDV with RBV	3	669	16	1.9 (0, 4.5)
SOF plus DCV with RBV	1	70	2	2.9 (1.0, 6.8)
PrOD with RBV	1	36	1	2.8 (0.1, 14.5)

CI, confidence interval; DCV, daclatasvir; LDV, ledipasvir; PR, pegylated interferon-ribavirin; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir